Assessing brain capillaries in coronavirus disease 2019
The European Parliament marked Brain Health Day: Prevention, Policy, Progress with a high‑level programme hosted by MEP Angelika Winzig, bringing renewed political attention to Europe’s urgent need for an integrated brain health strategy.
Latest Posts
-
-
Breaking newsCOVID-19ResearchReports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US—December 14, 2020-January 18, 2021
Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US—December 14, 2020-January 18, 2021 -
Breaking newsCOVID-19ResearchEffect of high-dose zinc and ascorbic acid supplementation vs usual care on symptom length and reduction among ambulatory patients with SARS-CoV-2 infection. The COVID A to Z randomized clinical trial
Effect of high-dose zinc and ascorbic acid supplementation vs usual care on symptom length and reduction among ambulatory patients with SARS-CoV-2 infection. The COVID A to Z randomized clinical trial -
Breaking newsCOVID-19ResearchEffect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial
Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial -
Breaking newsCOVID-19Research
Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial
Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial -
Breaking newsCOVID-19Research
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia -
Breaking newsCOVID-19Research
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial -
Breaking newsCOVID-19Research
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study -
Breaking newsCOVID-19Research
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial -
Breaking newsCOVID-19Research
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial -
Breaking newsCOVID-19ResearchSerum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report -
Patients using angiotensin-II-stimulating antihypertensives have 45% lower risk to develop demenia compared to those that use angiotensin-II-inhibiting antihypertensives. -
Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders
-
Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts
-
Longitudinal neuroimaging biomarkers differacross Alzheimer’s disease phenotypes